S'abonner

Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study - 27/08/11

Doi : 10.1016/S1470-2045(11)70165-6 
Hui-Wen Lin, PhD a, b, Ying-Yueh Tu, MD h, Shiyng Yu Lin, MD c, e, Wei-Ju Su, MA d, Wei Li Lin, BA c, Wei Zer Lin, BA i, Shen-Chi Wu, MD f, Yuen-Liang Lai, DrMD c, d, g, j,
a Department of Mathematics, Soochow University, Taipei, Taiwan 
b Biostatistics and Research Consultation Centre, Taipei Medical University, Taipei, Taiwan 
c School of Medicine, Taipei Medical University, Taipei, Taiwan 
d Graduate Institute of Humanities in Medicine, Taipei Medical University, Taipei, Taiwan 
e Department of Family Medicine, Taipei Medical University Hospital, Taipei, Taiwan 
f Department of Palliative Medicine, Taipei Medical University Hospital, Taipei, Taiwan 
g Department of Radiation Oncology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan 
h Department of Family Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan 
i School of Medicine, Chung Shan Medical University, Taichung, Taiwan 
j Mackay Medical College, Taipei, Taiwan 

* Correspondence to: Dr Yuen-Liang Lai, 291 Zhongzheng Road, Zhonghe City, Taipei County 235, Taiwan

Summary

Background

Ovarian cancer is commonly fatal and incidence has persistently risen in Taiwan over the past 20 years. Prevention strategies, however, are limited. Pelvic inflammatory disease (PID) has been suggested to increase the risk of developing ovarian cancer, but the results of studies have been inconsistent. Therefore, we investigated whether PID increases the risk of developing ovarian cancer in a large, nationwide cohort.

Methods

From the Longitudinal Health Insurance Database 2005 (LHID2005) in Taiwan, we obtained data for women aged 13–65 years for whom a diagnosis of PID, confirmed by multiple episodes, had been recorded between Jan 1, 2004, and Dec 31, 2005. We also obtained data for two controls per patient, matched for age and the year of first entry into the LHID2005. All patients were followed up from the date of entry in the LHID2005 until they developed ovarian cancer or to the end of 2006, whichever was earlier. We used Cox’s regression models to assess the risk of developing ovarian cancer, with adjustment for age, comorbid disorders, and socioeconomic characteristics.

Findings

We identified 67936 women with PID and 135872 controls. Among these 90 had developed ovarian cancer during the 3-year follow-up period (42 patients with PID and 48 controls, incidence 2·78 and 1·44 per 10000 person-years, respectively). The adjusted hazard ratio for ovarian cancer in patients with PID was 1·92 (95% CI 1·27–2·92) compared with controls, which rose to 2·46 (1·48–4·09) in women who had had at least five episodes of PID. The adjusted hazard ratio was slightly higher for women aged 35 years or younger with PID than in older women with PID (2·23, 1·02–4·79 vs 1·82, 1·10–3·04).

Interpretation

We found an association between PID and ovarian cancer. PID might, therefore, be a useful marker for ovarian cancer, and early treatment could help to improve prognosis. Whether pelvic inflammation itself accelerates the growth of ovarian cancers or affects cancer-cell differentiation in ways that adversely alter prognosis needs to be investigated.

Funding

None.

Le texte complet de cet article est disponible en PDF.

Plan


© 2011  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 12 - N° 9

P. 900-904 - septembre 2011 Retour au numéro
Article précédent Article précédent
  • Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial
  • Eva Johansson, Gunnar Steineck, Lars Holmberg, Jan-Erik Johansson, Tommy Nyberg, Mirja Ruutu, Anna Bill-Axelson, for the SPCG-4 Investigators ‡
| Article suivant Article suivant
  • Use of antineoplastic agents in patients with cancer who have HIV/AIDS
  • Michelle A Rudek, Charles Flexner, Richard F Ambinder

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.